EC Cancer

Case Report Volume 3 Issue 1 - 2025

Silent Osteonecrosis in a Young Osteosarcoma Survivor: A Case Report of Chemotherapy-Associated Osteonecrosis

Basma Dghoughi*, Kaoutar Maslouhi, Eric Michel Kessi Junior, Fatima-Zahra Laamrani, Youssef Omor, Rachida Latib and Sanae Amalik

Oncology Imaging Department, National Institute of Oncology, University Mohamed V Souissi, Rabat, Morocco

*Corresponding Author: Basma Dghoughi, Oncology Imaging Department, National Institute of Oncology, University Mohamed V Souissi, Rabat, Morocco.
Received: June 05, 2025; Published: July 15, 2025



Chemotherapy-associated osteonecrosis is a rare but significant complication of cancer treatment, characterized by bone necrosis resulting from disrupted vascular supply. This condition is most often associated with cytotoxic agents such as doxorubicin, cisplatin, and ifosfamide, which are known to inhibit angiogenesis, induce osteocyte apoptosis, and impair bone metabolism. MRI plays a crucial role in the early diagnosis with characteristic findings including serpiginous borders and distinct signal abnormalities on T1- and T2-weighted sequences. Although typically asymptomatic in its early stages, undetected osteonecrosis may progress to joint collapse, significantly impacting a patient’s quality of life. We report the case of a 28 years-old asymptomatic male, treated with chemotherapy for an osteosarcoma without any other relevant medical history, presenting imaging signs of osteonecrosis.

 Keywords: Osteonecrosis; Osteosarcoma; Chemotherapy; MRI

Basma Dghoughi., et al. “Silent Osteonecrosis in a Young Osteosarcoma Survivor: A Case Report of Chemotherapy-Associated Osteonecrosis”. EC Cancer  3.1 (2025): 01-05.